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Under physiological conditions, a bal-
ance between oxidants and antioxidants
exists. Reactive oxygen species (ROS), are
continuously generated by aerobic cells
and eliminated through scavenging sys-
tems to maintain redox homeostasis. The
two main sources of ROS are mito-
chondria and the NADPH oxidases fam-
ily, but ROS are produced also by the
cytochrome P450 system, xanthine oxidase
and nitric oxide synthase (Holmstrom
and Finkel, 2014). Because of ROS reac-
tivity toward lipids, proteins and DNA,
spatial and temporal regulatory strategies
exist to regulate their intracellular lev-
els. Excessive ROS levels are controlled
by specific intracellular enzymes, such
as superoxide dismutase (SOD), glu-
tathione peroxidase, catalase, thioredoxin
reductase, and glutathione S-transferase
(Glasauer and Chandel, 2014).
Cells aim to maintain a redox home-
ostasis: low levels of ROS, which are locally
produced, can be potent mitogens and
are required for various biological pro-
cesses such as cell survival, growth and
proliferation, angiogenesis, gene expres-
sion (Finkel, 2012). In contrast, changes
in redox balance result in oxidative stress
and aberrant cell signaling. Many studies
have shown the critical role of detoxifying
enzymes and antioxidant proteins in mod-
ulating the correct balance between apop-
tosis and carcinogenesis. Firstly, higher
ROS levels could play a causal role in
cancer development and progression by
inducing DNA mutations, genomic insta-
bility, aberrant pro-tumorigenic signaling.
After that, cancer cells adapt to oxida-
tive stress and counteract the potential
toxic effects of ROS to promote cell pro-
liferation, survival and metabolic adap-
tation to the tumor microenvironment:
sustained cell proliferation and mito-
genic signaling (Weinberg and Chandel,
2009), increased cell survival and disrup-
tion of cell death signaling (Clerkin et al.,
2008), epithelial to mesenchymal tran-
sition, metastasis (Nishikawa, 2008) and
angiogenesis (Ushio-Fukai andNakamura,
2008). Therefore, cancer cells are depen-
dent on maintaining high enough ROS
levels (redox imbalance) and an altered
redox environment that allow for pro-
tumorigenic cell signaling without induc-
ing cell death (Glasauer and Chandel,
2014).
Despite new discoveries and some
clinical successes, the major obstacle to
the effective treatment of human can-
cer is still the development of multidrug
resistance (MDR) (Simon and Schindler,
1994). The mechanisms involved are
complex and multifactorial (Baird and
Kaye, 2003), but it is now accepted
that classical redox transcription fac-
tors (NF-kB, HIF, p53, PI3K, AP-1) are
involved in the development of MDR.
Both carcinogenesis and MDR are fre-
quently associated with an increased
oxidative stress and activation of redox
metabolism: this could affect the efficacy
of cancer treatments by multiple mecha-
nisms, including apoptosis, angiogenesis,
metastasis, inflammatory reaction, and
chemosensitivity (Morrow et al., 2006;
Kuo, 2009). As a result, to balance oxida-
tive stress, cancer cells increase their
antioxidant capacity: according to our
experience, for example, glutathione
(GSH) plays a pivotal role in MDR
development.
Besides classical redox pathways many
studies recently focused on other redox-
sensitive factors. Nuclear factor-erythroid
2 related factor 2 (Nrf2), via its binding
to antioxidant response element (ARE),
regulates the expression of cytoprotec-
tive genes: classical antioxidant enzymes
including SOD and catalase, phase 2
detoxifying enzymes, and stress response
proteins such as heme oxygenase 1 (Kaspar
et al., 2009). In quiescent conditions, Nrf2
is anchored in the cytoplasm to Kelch-like
ECH-associated protein 1 (KEAP-1), an
adaptor protein which facilitates the Nrf2
ubiquitination and proteasomal degrada-
tion. Nrf2 nuclear accumulation is mainly
mediated by KEAP-1-dependent turnover:
its thiol-modification has long been asso-
ciated to a primary response to ROS pro-
duction (Dinkova-Kostova et al., 2002).
Owing to its cytoprotective functions,
Nrf2 has been traditionally studied in
the field of chemoprevention; however,
its overexpression or hyperactivation may
participate in tumorigenesis of a wide
number of solid cancers and leukemias
(Nioi and Nguyen, 2007; Shibata et al.,
2008; Homma et al., 2009). Moreover,
Nrf2 activity is connected with onco-
genic kinase pathways, structural pro-
teins, hormonal regulation, other tran-
scription factors, and epigenetic enzymes
involved in the pathogenesis of various
tumors (Gañán-Gómez et al., 2013). In
addition to protecting cells from ROS,
Nrf2 seems to play a direct role in MDR
acquisition in many cancer types. Recent
studies suggested a dark side of Nrf2
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pathway by showing that high level of
Nrf2 can promote cancer formation and
contribute to chemoresistance (Hayes and
McMahon, 2006; Lau et al., 2008; Wang
et al., 2008; Kensler and Wakabayashi,
2010; Gañán-Gómez et al., 2013). For
example, a greater nuclear accumulation
of Nrf2 leads to constitutive overexpres-
sion of ARE-containing genes includ-
ing drug efflux pumps, which facilitate
the development of resistance (Meijerman
et al., 2008). The expression of Nrf2 in
cancer cells is increased during acquired
resistance to doxorubicin and tamoxifen
in ovarian and breast cancer cells (Kim
et al., 2008; Kaspar et al., 2009). In addi-
tion, stable overexpression of Nrf2 or its
upregulation by tert-butylhydroquinone
resulted in enhanced resistance of can-
cer cells to some chemotherapeutic agents
(Wang et al., 2008). High expression of
Nrf2 and its target genes in MCF-7 and
MDA-MB-231 mammospheres compared
to corresponding adherent cells is asso-
ciated with increased resistance to taxol
and anchorage-independent growth (Wu
et al., 2014). Moreover, transport activ-
ities of several MDR-associated proteins
(MRPs) are regulated by GSH availability,
and γ-glutamylcysteine synthetase (GCS)
is the rate-limiting enzyme for its de novo
biosynthesis. Transcriptional regulation of
γ-GCS and MRP1 expression is medi-
ated by an ARE that contains a consensus
sequence for Nrf2; so, co-regulation of γ-
GCS and MRP1 would facilitate the efflux
activity (Glasauer and Chandel, 2014).
APE-1/Ref-1 (Apurinic-apyrimidinic
endonuclease 1/Redox Factor 1) is a mul-
tifunctional protein with both DNA repair
and transcriptional regulatory activities by
facilitating DNA binding of numerous
transcription factors involved in can-
cer promotion and progression, (AP-1,
NF-κB, HIF, CREB, p53) (Luo et al.,
2008). APE-1 requirement for cellular
survival and its frequent overexpression
in tumor cells strongly suggests a fun-
damental role in preventing cell death
and controlling proliferation (Tell et al.,
2005). Elevated APE-1 levels have been
found in ovarian, cervical, prostate can-
cers, rhabdomyosarcoma and germ cell
tumors (GCTs) correlating with the
tumors radiosensitivity (Evans et al.,
2000). Furthermore, immunohistochem-
istry in sections of GCTs from patients
with testicular cancer of various his-
tologies revealed high levels of APE-1
expression, suggesting a relation with their
relative resistance to therapy (Robertson
et al., 2001). Other evidences revealed
that APE-1 contributes to alkylating agent
resistance (Silber et al., 2002) or radioresis-
tance in human glioma cells (Naidu et al.,
2010), promotes resistance to radiation
plus chemotherapy in medulloblastoma
and primitive neuroectodermal tumors
and in pediatric ependymomas (Bobola
et al., 2011). Moreover, APE-1, preferably
in the acetylated form, stably interacts with
Y-box-binding protein 1 and enhances
its binding to the Y-box element, lead-
ing to the activation of the MDR1 gene.
Indeed, a systematic increase in both APE-
1 and MDR1 expression was observed in
non-small-cell lung cancer tissue samples
(Chattopadhyay et al., 2008).
Forkhead box O (FoxO) proteins are a
family of transcription factors that, reg-
ulated by several stimuli, modulate genes
involved in differentiation, proliferation,
survival, apoptosis, migration and DNA
repair (Dansen and Burgering, 2008; Yang
and Hung, 2009). Upon exposure to an
oxidative stress, FoxOs can lead to apop-
tosis or adaptive responses, depending
on the entity of the stress. FoxO pro-
teins have an important role in regulat-
ing cellular antioxidant defenses through
the induction of genes encoding Mn-SOD
and catalase; therefore, loss of FoxO func-
tion could contribute to increase the cel-
lular ROS levels, eventually leading to
DNA damage (Dansen and Burgering,
2008). FoxOs are deregulated in several
tumors including breast and prostate can-
cers, glioblastoma, rhabdomyosarcoma,
and leukemia (Myatt and Lam, 2007).
During tumor development, the inhibition
of FoxO3 transcriptional activity promotes
cell transformation, cancer progression,
and angiogenesis (Yang and Hung, 2009).
Therefore, FoxOs inactivation seems to be
an important step in carcinogenesis and
increasing their activity could represent
a therapeutic strategy (Myatt and Lam,
2007; Yang and Hung, 2009). Additionally,
under continuous stress FoxOs could also
induce the expression of important genes
for drug efflux and antioxidant defense:
the same molecules are responsible for
not only the initial therapeutic response
to cancer drugs, but also the subsequent
acquisition of drug resistance (Zhang et al.,
2011; Gomes et al., 2013). Sustained FoxO
activationmay promoteMDR and cell sur-
vival: FoxO3 and FoxO1 induce MDR1
expression respectively in K562 leukemic
cells and adriamycin-resistant breast can-
cer cells (Han et al., 2008; Yang and
Hung, 2009). In addition, the proximal
promoter region of the human MRP2
gene contains four putative FoxO bind-
ing sites, and its transcription was stimu-
lated by FoxO1 overexpression in MCF-7
cells (Choi et al., 2013). FoxO1 expres-
sion was distinctively upregulated in pacli-
taxel resistant cell line and enhanced by
exposure to paclitaxel with subcellular
translocation; in addition, FoxO1 over-
expression was frequently observed in
cancer tissue samples from chemoresis-
tant patients (Goto and Takano, 2009).
Paradoxically, cytostatic and cytotoxic
effects of a diverse spectrum of anti-cancer
drugs, such as paclitaxel, doxorubicin, lap-
atinib, gefitinib, imatinib, and cisplatin,
are mediated through the FoxO3 activa-
tion and/or the inhibition of its direct
target FOXM1. Moreover, there are also
studies in which cisplatin-resistant cells
had decreased levels of FoxO3 expression
and were more sensitive to the anticancer
agent mithramycin than their parental
cells: FoxO3 knockdown increased cell
proliferation and resistance to cisplatin
(Shiota et al., 2010). However, deregula-
tion of FoxOs has been recently found
also in leukemia, where active FoxOs
maintain leukemia stem cells and stimu-
late drug resistance genes, contributing to
leukemogenesis (Zhu, 2014).
Several approaches have been under-
taken to combat MDR. In the light of
these findings, modulation of cellular
redox levels could have important impli-
cations for the development of potential
anticancer therapies. Several reports have
demonstrated that Nrf2 silencing in can-
cer cells could decrease cell proliferation
and enhance sensitivity to chemothera-
peutic agents in lung, gallbladder, and
ovarian tumors (Meijerman et al., 2008;
Singh et al., 2008). Very recently, brusatol,
an inhibitor of the Nrf2 pathway, was
discovered to suppress Nrf2 level and
its target genes, enhancing intracellular
ROS, sensitizing MCF-7 and MDA-MB-
231 mammosphere cells to taxol and
reducing anchorage-independent growth
Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs December 2014 | Volume 5 | Article 286 | 2
Polimeni and Gazzano Redox signaling and multidrug resistance
(Wu et al., 2014). Reducing the APE-1
amount in cancer using RNA interfer-
ence and antisense oligonucleotide tech-
nology sensitizes tumor cells to a variety
of chemotherapeutic agents. For example
treatment of a human pancreatic cancer
cell line (Panc-1) with antisense oligonu-
cleotides to APE-1 resulted in a dramatic
increase in gemcitabine sensitivity (Lau
et al., 2004). Therefore, selective APE-
1 activity inhibition could have poten-
tial therapeutical significance and be a
promising avenue to develop novel can-
cer treatments (Jiang et al., 2008; Bapat
et al., 2009). APE-1 may be a useful
target for modifying radiation tolerance:
the inhibitors lucanthone and CRT004876
were employed, the former a thioxanthene
previously under clinical evaluation as a
radiosensitizer for brain tumors and the
latter a more specific inhibitor (Naidu
et al., 2010); knockdown of APE-1 gene
expression may significantly sensitize pan-
creatic cancer cells to radiotherapy (Chen
et al., 2013). Finally, some studies demon-
strated that Bcl-2 could directly interact
with APE-1 via its BH domains: gossypol,
a Bcl-2 homology 3 (BH3)-mimetic agent
binds to the BH3 domain of Bcl-2 family
members and inhibits the repair activity
and the redox function of APE-1 (Qian
et al., 2014). Because of its pivotal role in
drug sensitivity as well as resistance, the
complex of FoxO could be a viable strat-
egy for cancer treatment and drug resis-
tance overcoming, while in cancer patients
might also help to predict and monitor
their clinical response to chemotherapy.
Although in the past antioxidants were
seen as tumor suppressors, recent research
uncovered the “dark side of antioxidants”
(Wang et al., 2008; Sayin et al., 2014),
which are used by cancer cells to pro-
mote survival and growth. The depen-
dence of cancer cells on ROS homeostasis
may represent the cancer cell’s “Achilles
Heel” and could be potentially exploited
to target them therapeutically: pro-oxidant
cancer therapy can affect the different ROS
production and redox regulation between
normal and cancer cells. At last, recent
discoveries about Nrf2, APE-1, FoxO and
their potential contribution in the devel-
opment, maintenance and evolution of
MDR in cancer, open a novel therapeutic
window for cancer treatment. High levels
of ROS can be toxic to cancer cells and
potentially induce cell death via oxidative
stress while sparing normal cells. Therein,
redox modulators could be promising
tools in MDR cancer prevention and treat-
ment; nevertheless, because of the com-
plexity underlying drug resistance, it will
be necessary to do careful antioxidant pro-
filing of tumor cells to identify clinically
relevant therapeutic targets.
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